DOI: 10.36347/sasjs

Pages: 186-190

Verapamil, a calcium channel blocker, is useful for the treatment of Peyronie’s disease. We report our experience of intralesional injection of verapamil among Indian patients with Peyronie’s disease. A total of 42 consecutive patients with Peyronie’s disease were treated with intralesional injection of verapamil between September 2015 and January 2017. Patients with Peyronie’s disease if suitable were offered treatment with intralesional injection of verapamil 10 mg (biweekly for 6 months). Change in plaque size, penile curvature, pain and impartment in sexual performance were assessed. Overall, the mean age was 41 years. Majority (85.7%) of patients had single plaque, 54.8% of patients had mild penile curvature. Overall, plaque size was reduced in 23 patients from 2.42 cm to 1.01 cm in length, from 1.12 cm to 0.53 cm in width and from 1.41 ml to 0.60 ml in volume. Twenty-eight patients had decrease in penile curvature and 95.23% of patients were relieved of pain during erection. Thirty-one patients reported improved quality of erection. Overall, the verapamil was well tolerated with no new safety signals. Intralesional verapamil injection reduced pain, plaque size and penile curvature in Indian patients with Peyronie’s disease. Intralesional verapamil can be considered as a first-line treatment in the great majority of patients